# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Friedrich Nietzsche (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI019-SYN-TD
- Date: 1881-07-07
- Fictional facility: St. Posthumous Health Center
- Fictional author: Konrad Ellison-Mbatha, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- Headaches on most days that stop him reading and writing, despite moving between climates to escape them **S**
- He fears that a brain illness like the one that killed his father may lie behind the headaches **S**
- Very poor sight in the right eye and tired eyes when reading **S**
- Short, broken sleep **S**

## Your goals

- A two-week headache diary and the tests that allow a firm diagnosis. Target: 1881-07-21. Recorded outcome: Diary of 14 days kept; ICHD-3 criteria for chronic migraine and medication overuse headache met; MRI normal; syphilis serology nonreactive. **S**
- Stop the butalbital combination safely. Target: 1881-08-18. Recorded outcome: Three-week taper completed a week before the four-week review; no withdrawal seizure or delirium; withdrawal headache settled within ten days. **S**
- Fewer than 15 headache days a month, and at least half as many migraine days, within three months of starting prevention. Target: 1881-10-13. Recorded outcome: At eight weeks: headache days 20 to 7 and migraine days 12 to 4 in the past four weeks; the three-month review is due. **S**
- Acute medicine on no more than eight days a month after withdrawal. Target: 1881-09-15. Recorded outcome: Acute medicine on 5 days in the past four weeks; no butalbital or combination product since the taper. **S**
- Clear vision in the left eye for reading and protection of the right eye. Target: 1881-08-18. Recorded outcome: Contact lenses fitted; left eye 20/20 and right eye 20/100 corrected; knows the warning signs of retinal detachment. **S**
- Six and a half hours of sleep on most nights without sleeping tablets. Target: 1881-10-13. Recorded outcome: Five and a half to six hours at eight weeks with CBT-I under way. **S**

## What we agreed to do

- Diagnosis: a structured headache history, a red-flag screen (SNNOOP10) at every visit, a 14-day diary of headache days, attack features, triggers and every dose of acute medicine, and ICHD-3 criteria; MRI of the brain with and without contrast because the headaches have become more frequent over the past year, are strongly right-sided, and come with long-standing unequal pupils and a very poor right eye; treponemal and nontreponemal syphilis serology because of past gonorrhea, unequal pupils and poor vision. Guideline: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018); The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013); Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) **S**
- Neurology (headache medicine) consultation to confirm the diagnosis and advise on withdrawal of the overused tablets and on preventive treatment. Guideline: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024); European Academy of Neurology guideline on the management of medication-overuse headache (2020) **S**
- Medication overuse at intake: explain how frequent combination tablets can keep headaches going; count every tablet and acute-medicine day in the diary; take no more than now and never more than four combination tablets a day until the consultation; no new sedatives or sleeping tablets. Guideline: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018); European Academy of Neurology guideline on the management of medication-overuse headache (2020) **S**
- Comprehensive eye examination for high myopia: refraction, pupils, pressure, a dilated fundus examination for myopic degeneration, retinal breaks and lattice, and macular OCT; correction of the large difference between the eyes; the warning signs of retinal detachment and an Amsler grid; dilated examination every year. Guideline: Refractive Errors Preferred Practice Pattern (2023); Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern (2025); Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern (2026) **S**
- Withdrawal: stop ibuprofen and replace as-needed butalbital combination tablets with a scheduled three-week taper (twice a day, then once a day, then every other day), because barbiturates are tapered rather than stopped abruptly; warn about rebound headache in the first one to two weeks and about the rare risk of withdrawal seizures; start prevention at the same time. Guideline: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); European Academy of Neurology guideline on the management of medication-overuse headache (2020); European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update (2022) **S**
- Acute treatment after withdrawal: naproxen with metoclopramide early in an attack, no more than two days a week; sumatriptan added once the taper is complete, with no more than eight triptan days a month; no butalbital, opioids or combination products with caffeine. Guideline: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); European Academy of Neurology guideline on the management of medication-overuse headache (2020); Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013) **S**
- Preventive treatment for chronic migraine: galcanezumab 240 mg loading dose, then 120 mg monthly, judged at three months (at least half as many monthly migraine days); topiramate not chosen because of its effects on word-finding and concentration and its rare acute myopia with angle-closure glaucoma, a poor fit for a writer with high myopia; erenumab not chosen because of his constipation; onabotulinumtoxinA, every 12 weeks, as the next option or an addition. Guideline: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024); European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update (2022); Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation (2018) **S**
- Sleep: cognitive behavioral therapy for insomnia through the clinic's behavioral sleep program, a fixed rising time, a wind-down hour, and no sedative sleeping tablets. Guideline: Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline (2021) **S**
- Mood: PHQ-9 and GAD-7 at intake and at about two to three months, with direct questions about hopelessness and self-harm at each visit; a safety assessment if a score or answer calls for one. Guideline: CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Reading, writing and walking: good light, large print and an enlarged screen, breaks every 30 minutes, voice dictation for long passages, sunglasses and a brimmed hat for glare, and his daily walks kept as a protected part of the plan. Guideline: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Refractive Errors Preferred Practice Pattern (2023) **S**

## Follow-up

- 1881-07-07: Establishing primary care for frequent disabling headaches with nausea and light sensitivity: headache history and red-flag screen, a headache diary, disability and mood screening, the daily combination tablets, MRI and syphilis serology, his eyes and his sleep **S**
- 1881-07-21: Two-week review of the headache diary, the MRI and the comprehensive eye examination, seen the same day by headache medicine: diagnosis, withdrawal of the overused tablets and preventive treatment **S**
- 1881-08-18: Four-week review after starting galcanezumab and the taper: withdrawal, headache days, acute medicine and the second injection **S**
- 1881-09-01: Periodic adult preventive visit **S**
- 1881-09-15: Eight-week review of prevention: headache days, disability, mood, sleep and the plan ahead **S**

This teaching document does not replace care from a qualified clinician.
